Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010–2011

  • 1, 2Email author,
  • 3, 4,
  • 6,
  • 8, 9,
  • 1, 2,
  • 3, 4,
  • 1,
  • 5,
  • 1, 2,
  • 7,
  • 1,
  • 1, 10,
  • 1, 5 and
  • 1, 2Email author
BMC Infectious Diseases201515:26

https://doi.org/10.1186/s12879-015-0746-x

©  Walaza et al.; licensee BioMed Central. 2015

  • Received: 26 August 2014
  • Accepted: 6 January 2015
  • Published:
Open Peer Review reports

Abstract

Background

Data on the association between influenza and tuberculosis are limited. We describe the characteristics of patients with laboratory-confirmed tuberculosis, laboratory-confirmed influenza and tuberculosis-influenza co-infection.

Methods

Patients hospitalized with severe respiratory illness (acute and chronic) were enrolled prospectively in four provinces in South Africa. Naso/oropharyngeal specimens were tested for influenza virus by real time reverse transcriptase polymerase chain reaction. Tuberculosis testing was conducted as part of clinical management.

Results

From June 2010 through December 2011, 8032 patients were enrolled and influenza testing was conducted on 7863 (98%). Influenza virus was detected in 765 (10%) patients. Among 2959 patients with tuberculosis and influenza results, 2227 (75%) were negative for both pathogens, 423 (14%) were positive for tuberculosis alone, 275 (9%) were positive for influenza alone and 34 (1%) had influenza and tuberculosis co-infection. On multivariable analysis amongst individuals with symptoms for ≥7 days, tuberculosis influenza co-infection was associated with increased risk of death, (adjusted relative risk ratio (aRRR) (6.1, 95% confidence interval (CI) 1.6-23.4), as compared to tuberculosis only infection. This association was not observed in individuals with symptoms for <7 days (aRRR.0.8, 95% CI 0.1-7.0).

Conclusion

Tuberculosis and influenza co-infection compared to tuberculosis single infection was associated with increased risk of death in individuals with symptoms ≥7 days. The potential public health impact of influenza vaccination among persons with laboratory-confirmed tuberculosis should be explored.

Keywords

  • Influenza
  • Tuberculosis
  • Co-infection
  • South Africa

Background

Despite the availability of efficacious treatment, tuberculosis remains the second most common cause of infectious disease–related deaths worldwide, after human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) [1]. In 2010, there were an estimated 8.8 million incident cases of tuberculosis globally [2]. HIV infection is an important risk factor for tuberculosis, and HIV-infected individuals have a 20 times greater risk of developing tuberculosis as compared to HIV-uninfected individuals [3]. In South Africa, there were an estimated 390,000 incident cases of tuberculosis in 2011 and 65% were co-infected with HIV [1].

Similarly, despite the availability of effective vaccines, influenza virus infection causes substantial annual morbidity and mortality worldwide and in South Africa [4-6]. Globally, it is estimated that influenza epidemics result in three to five million cases of severe illness, and about 250,000-500,000 deaths annually [4]. In 2010 an estimated 12 million episodes of severe and 3 million episodes of very severe acute lower respiratory tract infection resulted in hospital admissions in children <5 years worldwide [5]. A number of risk factors are described for severe outcomes among patients with influenza; these include extremes of age, chronic underlying diseases, pregnancy and immune-suppression [6]. HIV-infected individuals have an increased risk of influenza-associated hospitalisations and mortality [7].

While chronic lung diseases are a known risk factor for severe outcome due to influenza infection, there are few published data on the association between influenza and tuberculosis. Review of data from the 1918 influenza pandemic suggests that individuals with tuberculosis had a disproportionately higher mortality than the general population [8,9] and that underlying tuberculosis infection may have contributed to the elevated mortality observed in young adults [8,10]. There is little information about the interaction between seasonal or pandemic influenza and tuberculosis in recent years. In South Africa, 10% of cases that died during the 2009 A(H1N1)pdm09 pandemic were co-infected with tuberculosis [11]. In South Korea, concurrent tuberculosis and influenza A(H1N1)pdm09 infection was reported in 7 immunocompetent patients, none resulting in fatal outcome [12].

We describe the epidemiological and clinical characteristics of patients admitted with laboratory-confirmed tuberculosis, influenza and tuberculosis-influenza co-infection among patients hospitalized with severe respiratory illness (SRI) in South Africa, a country with a high prevalence of HIV.

Methods

Study design

We conducted prospective hospital-based active surveillance for Severe Acute Respiratory Illness (SARI) surveillance at 6 public hospitals in 4 surveillance sites situated across the country: Chris Hani Baragwanath Academic Hospital (CHBAH), Gauteng Province; Edendale Hospital, KwaZulu-Natal Province; the two hospitals of the Klerksdorp–Tshepong Hospital Complex (KTHC), Northwest Province; and Mapulaneng and Matikwana Hospitals, Mpumalanga Province [13]. At each sentinel hospital trained surveillance officers screened all admitted patients for surveillance inclusion criteria from Monday to Friday, except at CHBAH where adult patients were screened on 2 of every 5 days per week because of large patient numbers.

Case definitions

A case of SARI was defined as a hospitalised individual with onset of illness within seven days of admission meeting age-specific clinical inclusion criteria. We included children aged two days through <3 months with physician-diagnosed sepsis or acute lower respiratory tract infection (ALRI), children aged three months through <5 years with physician-diagnosed ALRI (including, for example bronchitis, bronchiolitis, pneumonia and pleural effusion) and patients aged ≥5 years meeting a modified World Health Organization (WHO) case definition for SARI including sudden onset of fever (>38°C) or reported fever, cough or sore throat, and shortness of breath or difficulty breathing [14]. In addition expanded case definitions were applied at three of the hospitals in two of the surveillance sites, (Edendale Hospital and KTHC) to include individuals meeting the above case definition but with symptoms for >7 days and individuals with suspected or confirmed tuberculosis; these patients were defined as having severe chronic respiratory illness (SCRI). For this analysis severe respiratory illness (SRI) was used to refer to all enrolled patients i.e. patients admitted with an acute or chronic respiratory illness.

The South African National Department of Health tuberculosis case definitions were modified to define suspected tuberculosis [15]. A suspected tuberculosis case in children <12 years was defined as: i) any child presenting with a history of exposure to an infectious tuberculosis case or with a positive tuberculin skin test and symptoms of tuberculosis (chronic cough, weight loss and fever) with or without an abnormal chest x-ray suggestive of tuberculosis, or ii) admitted with a physician diagnosis of tuberculosis or suspected tuberculosis, or iii) initiated on tuberculosis treatment on admission; or iv) was on tuberculosis treatment for <2 months at the time of admission. A suspected tuberculosis case in individuals ≥12 years of age was defined as: i) any patient presenting with night sweats, chronic cough, weight loss or haemoptysis lasting for >2 weeks, or ii) had a physician diagnosis of tuberculosis or suspected tuberculosis, or iii) was initiated on tuberculosis treatment on admission, or iv) was on tuberculosis treatment for <2 months at the time of admission.

Patients who were on tuberculosis treatment for ≥2 months at the time of admission were not enrolled into the surveillance programme as cases of suspected or confirmed tuberculosis (because we assumed that after two months of treatment tuberculosis was no longer the reason for their clinical presentation). These patients were, however, enrolled if they met the criteria for SARI. The tuberculosis status of the enrolled patients was based on results of tuberculosis testing at current admission.

For this analysis, a laboratory-confirmed tuberculosis case was defined as an individual with a positive result for Mycobacterium tuberculosis on microscopy, culture or polymerase chain reaction (PCR) by GeneXpert MTB/RIF test (Cepheid, Sunnyvale, California) from the current hospital admission or from a specimen taken within two weeks preceding or following the admission. An influenza case was defined as an individual with a positive PCR test for influenza. An influenza-tuberculosis co-infection case met criteria for both laboratory-confirmed tuberculosis and influenza during the same admission.

Data collection

A standardized questionnaire was used to collect demographic and clinical data, medical history of the patient and in-hospital outcome. Hospital and intensive care unit (ICU) admission and collection of specimens for bacterial culture, tuberculosis testing and CD4+ T-cell counts were performed according to attending-physician discretion.

Sample collection and processing

Respiratory specimens (oropharyngeal and nasopharyngeal swabs for patients ≥5 years of age or nasopharyngeal aspirates for children <5 years of age), were collected and placed in 4 ml virus transport medium. Whole blood samples were collected in EDTA-containing vacutainer tubes within 24 hours of hospital admission for the detection of Streptococcus pneumoniae and HIV infection.

After collection, respiratory and blood samples were kept at 4°C at the sentinel site, and transported on ice at least twice per week to the National Institute for Communicable Diseases of the National Health Laboratory Services (NICD-NHLS) for testing.

Detection of respiratory viruses and S. pneumoniae

Respiratory samples were tested by multiplex real-time reverse-transcription polymerase chain reaction (PCR) (rRT-PCR) for influenza type A and B, adenovirus, enterovirus, rhinovirus, human metapneumovirus, respiratory syncytial virus and parainfluenza virus types 1–3 [16]. The influenza A positive specimens were subtyped using the Centers for Disease Control and Prevention (CDC) rRT-PCR protocol for detection and characterization of influenza. DNA was extracted from whole blood specimens using the MagNA Pure LC 2.0 instrument and DNA Isolation kit III for bacteria (Roche, Mannheim, Germany) and were tested for the S. pneumoniae lytA gene by a quantitative real-time PCR [17].

Determination of HIV infection

HIV status data were obtained from two data sources. Some patients had HIV testing requested by admitting physicians as part of clinical care. This included HIV enzyme-linked immunosorbent assay (ELISA) testing with confirmation by ELISA on a second specimen for patients ≥18 months of age and qualitative HIV PCR testing for confirmation of HIV-infection status in children <18 months of age. In addition, for consenting patients, linked anonymous HIV PCR testing for children <18 months of age or ELISA for patients ≥18 months of age was performed using a dried blood spot or whole blood specimen at the NICD-NHLS laboratory.

Determination of tuberculosis infection

Testing for M. tuberculosis, including microscopy, culture, GeneXpert MTB/RIF test, or a combination of these, was undertaken at the discretion of the attending-physician and performed at the laboratory serving the hospital where the patient presented. Specimens for tuberculosis testing were examined by light microscopy for the presence of acid fast bacilli. Tuberculosis culture was performed using the BACTEC MGIT automated culture system (Becton Dickinson, Franklin Lakes, New Jersey). Tuberculosis PCR was performed using the Xpert MTB/RIF system (Cepheid, Sunnyvale, California). The GeneXpert MTB/RIF is an automated sample processing and nucleic acid amplification test for detection of M. tuberculosis and is able to detect resistance to rifampicin. The National Department of Health tuberculosis treatment guidelines recommended treatment for patients with positive smears and that patients suspected of tuberculosis should have two specimens tested on microscopy and if these were negative then a 3rd sample should be tested for smear and culture [15].

Data analysis

To identify factors associated with tuberculosis testing, tuberculosis positivity and tuberculosis-influenza co-infection we included both potential determinants for, as well as outcomes or characteristics of the primary endpoints of the analysis. Univariate comparisons were performed using logistic or multinomial regression. In addition, we implemented three multivariable models to identify factors associated with: (i) tuberculosis testing among enrolled patients; (ii) tuberculosis positivity among enrolled patients tested for tuberculosis; and (iii) tuberculosis single infection compared to influenza single infection or tuberculosis-influenza co-infection. The tuberculosis testing and positivity models were implemented using stepwise forward selection logistic regression. Multinomial regression was used for the comparison of tuberculosis only, influenza only and tuberculosis-influenza co-infected groups and this analysis was performed separately in individuals with symptoms for <7 days and ≥7 days. Multinomial regression allows modelling of outcome variables with >2 categories and relates the probability of being in category j to the probability of being in a baseline category. A complete set of coefficients are estimated for each of the j levels being compared with the baseline and the effect of each predictor in the model is measured as relative risk ratio (RRR). For this analysis, we used the tuberculosis single infection group as the baseline category and compared it with the influenza single infection and tuberculosis-influenza co-infection groups and we restricted the analysis to laboratory confirmed cases for both influenza and tuberculosis. The general form of the multivariable multinomial model with dichotomous predictors was as follows:
$$ \ln \frac{p\left({Y}_j\right)}{p\left({Y}_1\right)}={\beta}_0^{(j)}+{\beta}_1^{(j)}{X}_1+\dots +{\beta}_n^{(j)}{X}_n+\varepsilon $$
(1)

Where p(Y 1 ) is the probability of the outcome variable in the base category (tuberculosis single infection) and p(Y j ) is the probability of the outcome variable in the other categories; j represents the two other categories (j = 2: influenza single infection; and j = 3: tuberculosis-influenza coinfection) that are compared to the base category; \( {\beta}_0^{(j)} \) is the model constant for category j; \( {\beta}_1^{(j)} \) to \( {\beta}_n^{(j)} \) are coefficients associated with predictors X 1 to X n in category j; and ε is the error term.

The model in equation 1 was fitted to any enrolled case with available tuberculosis and influenza results irrespective of duration of symptoms as well as separately among individuals with acute (duration of symptoms <7 days) and chronic (duration of symptoms ≥7 days) clinical presentation to specifically assess the clinical characteristics of individuals within these two groups. In order to allow for direct comparison of the final multivariable models for acute and chronic patients we elected to retain any variable which was significant at 0.05 in either one of these models in the final multivariable model. Covariates with a p-value <0.2 at the univariate analysis were assessed for significance at the multivariable analysis and statistical significance was assessed at p < 0.05 for all models. Statistically significant variables were retained in the multivariable models. HIV status was retained in the multinomial models a priori as this is a potential confounder of the interaction between influenza and tuberculosis. Two-way interactions were assessed by inclusion of product terms for all variables remaining in the final additive models. The statistical analysis was implemented using STATA® version 12 (StataCorp, Texas, USA).

Ethics

Ethical approval for the study was obtained from the University of the Witwatersrand, Human Research Ethics committee (reference M081042) and the University of KwaZulu-Natal Biomedical Research Ethics committee (reference BF157/08). The United States Centers for Disease Control and Prevention deemed this surveillance not to be research and therefore this project did not need human subjects review.

Results

Patient enrolment and testing

From June 2010 through December 2011, we enrolled 8032 patients, and influenza results were obtained from 7863 (98%) cases (Figure 1). Of these 4077 (52%) were females and 3291 (42%) were children ≤5 years. Influenza virus was detected in 765 (10%) patients. An influenza subtype was characterized from 764 (99.8%) influenza positive samples, including 219 (29%) influenza A(H1N1)pdm09, 195 (25%) A(H3N2) and 350 (46%) influenza B. Among patients with available influenza results, 2959 (38%) were tested for tuberculosis during admission. Of these, 69% (2029) and 31% (930) met the SARI and SCRI case definitions, respectively. HIV results were available for 2739 (93%) of 2959 patients with available tuberculosis results and 1877 (69%) were HIV-infected. Among influenza tested patients with available data <1% (6/7863) received oseltamivir and <1% (4/7857) were vaccinated against influenza. Two percent (179/7863) of enrolled patients with results for influenza and 2% (49/2959) of those tested for influenza and tuberculosis were already receiving tuberculosis treatment at time of current admission.
Figure 1
Figure 1

Flow chart of patients enrolled into the severe respiratory illness (acute and non acute) surveillance, South Africa 2009-2011.

Factors associated with tuberculosis testing on admission

Among patients with available influenza results, on multivariable analysis factors associated with tuberculosis testing were age ≥5 years, with the highest proportion tested (56%, 1378/2473) in the 25–44 age group (adjusted odds ratio (aOR) 3.5, 95% CI 3.0-4.2) as compared to age <5 years, HIV infection (aOR 1.5, 95% CI 1.3- 1.7), symptom duration ≥7 days (aOR 1.3, 95% CI 1.1-1.5), hospitalisation duration >7 days (aOR 1.3, 95% CI 1.1- 1.4), requiring oxygen therapy (aOR 1.2, 95% CI 1.0-1.3) and antibiotic (aOR 1.9, 95% CI 1.4-2.5) or tuberculosis (aOR 1.2, 95% CI 1.0-1.4) treatment started during current admission (Table 1). The proportion of patients tested for tuberculosis was similar for patients testing influenza-positive and influenza-negative and for those who died in-hospital and those who survived.
Table 1

Demographic and clinical characteristics of patients admitted with severe respiratory illness (acute and chronic), by tuberculosis testing status at four sites in South Africa, June 2010- December 2011

Characteristic

 

Tested for tuberculosis n/N (%)

Unadjusted odds ratio (95% CI)

P value

Adjusted odds ratios (95% CI)

P value

Age group (years)

0-4

571/3291 (17)

Reference

 

Reference

 
 

5-24

270 /587 (46)

4.05 (3.4-4.9)

<0.001

3.3 (2.6-4.1)

<0.001

 

25-44

1378/2473 (56)

5.99 (5.3-6.8)

<0.001

3.5 (3.0-4.2)

<0.001

 

45-64

611/1197 (51)

4.96 (4.3-5.7)

<0.001

3.2 (2.7-3.8)

<0.001

 

≥65

129/315 (39)

3.30 (2.6-4.2)

<0.001

2.6 (2.0-3.4)

<0.001

Sex

Female

1664/4077 (41)

Reference

   
 

Male

1295/3786 (34)

0.8 (0.7-0.8)

<0.001

  

Site

Chris Hani Baragwanath

1618/4437 (36)

Reference

 

Reference

 
 

Mapulaneng & Matikwana

144/749 (19)

0.4 (0.3-0.5)

<0.001

0.4 (0.3-0.5)

<0.001

 

Edendale

385/1156 (33)

0.9 (0.8-0.99)

0.046

0.7 (0.6-0.8)

<0.001

 

Klerksdorp/Tshepong

812/1521 (53)

1.99 (1.8-2.2)

<0.001

1.1 (0.95-1.3)

0.152

Influenza

Negative

2650/7098 (37)

Reference

   
 

Positive

309/765 (40)

1.1 (0.9-1.3)

0.097

  

HIV status

Negative

862/3410 (25)

Reference

 

Reference

 
 

Positive

1877/3523 (53)

3.4 (3.0-3.7)

<0.001

1.5 (1.3-1.7)

<0.001

Underlying medical condition*

No

2652/7041 (38)

Reference

   

Yes

307/821 (37)

0.98 (0.85-1.14)

0.879

  

Duration of symptoms prior to admission (days)

<7

1884/5957(32)

Reference

 

Reference

 

≥7

1012/1765 (57)

2.9 (2.6-3.2)

<0.001

1.3 (1.1-1.5)

0.003

Concurrent invasive bacterial infection**

No

653/1832 (36)

Reference

   

Yes

24/46(52)

1.96 (1.1- 3.5)

0.023

  

Pneumococcal

No

2435/6284 (39)

Reference

   

Infection***

Yes

214/434 (49)

1.5 (1.3-1.9)

<0.001

  

Receiving tuberculosis treatment at time of admission

No

158/292 (54)

Reference

<0.001

  

Yes

49/179 (27)

0.3 (0.2-0.5)

   

Started on treatment for tuberculosis

No

2301/6716 (34)

Reference

 

Reference

 

Yes

647/1108 (58)

2.7 (2.4-3.1)

<0.001

1.2 (1.0-1.4)

0.036

Antibiotics prescribed

No

77/332 (23)

Reference

 

Reference

 

Yes

2877/7515 (38)

2.1 (1.6-2.7)

<0.001

1.9 (1.4-2.5)

<0.001

Oxygen therapy

No

1869/5145 (36)

Reference

   
 

Yes

1086/2698 (40)

1.2 (1.1-1.3)

0.001

1.2 (1.0-1.3)

0.018

ICU admission

No

2936/7772 (38)

Reference

   
 

Yes

15/65 (23)

0.5 (0.3-0.9)

0.017

  

Duration of hospitalisation (days)

≤7

1913/5666 (34)

Reference

 

Reference

 

>7

1029/2143 (48)

2.9 (2.6-3.2)

<0.001

1.2 (1.1-1.4)

0.002

Died

No

2757/7321 (38)

Reference

Reference

  
 

Yes

195/509 (38)

1.02 (0.9-1.2)

0.769

  

HIV – human immunodeficiency virus; ICU– intensive care unit, TB-Tuberculosis.

*Underlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus, immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.

**Concurrent invasive bacterial infections were defined as a bacterial pathogen isolated from blood, cerebrospinal fluid or another sterile site from a specimen taken within 48 hours of hospitalisation; organisms viewed as likely contaminants were excluded.

***Pneumococcal co-infection (lyt A PCR positive for Streptococcus pneumoniae on blood specimen).

Other variables evaluated but not presented in the table because they were not significant on univariate analysis were, Oseltamivir treatment prescribed and smoking and alcohol intake for patients ≥12 years.

Factors associated with laboratory-diagnosed tuberculosis

Among 2959 patients with available tuberculosis and influenza results, 15% (457/2959) tested positive for tuberculosis on the current admission and 2% (10/457) of these were receiving tuberculosis treatment at time of current admission. The highest percentage testing tuberculosis positive was in the 25–44 years age group (18%, 249/1378) (Table 2). Of the patients testing positive for tuberculosis, 332 (73%) were positive on microscopy only. The tuberculosis detection rate was 10% among those with symptoms for <7 days and 25% among those with symptoms for ≥7 days. Of the 457 laboratory-confirmed tuberculosis cases, 198 (43%) and 259 (57%) met the SARI and SCRI case definitions respectively. On multivariable analysis, patients with laboratory-diagnosed tuberculosis were less likely to be co-infected with S. pneumoniae (aOR 0.5, 95% CI 0.3-0.9) and to have received oxygen therapy (aOR 0.7, 95% CI 0.5- 0.9). They were more likely to be admitted at KTHC as compared to CHBAH (aOR 1.9, 95% CI 1.4-2.6) and to be started on tuberculosis treatment at current admission (aOR 4.6, 95% CI 3.5-6.0) (Table 2).
Table 2

Demographic and clinical characteristics associated with laboratory-confirmed tuberculosis among patients admitted with severe respiratory illness (acute and chronic) that were tested for tuberculosis and influenza at four sites in South Africa, June 2010- December 2011

Characteristic

 

Laboratory confirmed tuberculosis n/N (%)

Unadjusted odds ratio (95% CI)

P value

Adjusted odds ratios (95% CI)

P value

Age group (years)

0-4

55/571 (10)

Reference

 

Reference

 
 

5-24

47/270 (17)

1.97 (1.3-3.0)

0.001

1.36 (0.8-2.3)

0.233

 

25-44

249/1378 (18)

2.1 (1.5-2.8)

<0.001

1.37 (0.9-2.06)

0.120

 

45-64

90/611 (15)

1.6 (1.1-2.3)

0.008

1.11 (0.7-1.7)

0.628

 

65+

16/129 (12)

1.3 (0.7-2.4)

0.348

0.94 (0.5-1.9)

0.872

Site

Chris Hani Baragwanath

141/1618 (9)

Reference

 

Reference

 

Mapulaneng & Matikwana

23/144 (16)

1.99 (1.2-3.2)

0.005

1.4 (0.8-2.3)

0.228

Edendale

49/385 (13)

1.5 (1.1-2.2)

0.016

0.9 (0.6-1.4)

0.668

Klerksdorp/Tshepong

244/812 (30)

4.5 (3.6-5.6)

<0.001

1.9 (1.4-2.6)

<0.001

Influenza status

Negative

423/2650 (16)

Reference

   
 

Positive

34/309 (11)

0.7 (0.5-0.9)

0.023

  

HIV status

Negative

89/862 (10)

Reference

   
 

Positive

335/1877 (18)

1.9 (1.5-2.4)

<0.001

  

Underlying medical condition*

No

426/2652 (16)

Reference

   

Yes

31/307 (10)

0.6 (0.4-0.9)

0.007

  

Duration of symptoms prior to admission

<7

190/1884 (10)

Reference

   

≥7

255/1012 (25)

3.0 (2.4-3.7)

<0.001

  

Pneumococcal co-infection on PCR**

No

400/2435 (16)

Reference

 

Reference

 

Yes

18/214 (8)

0.5 (0.3-0.8)

0.003

0.5 (0.3-0.9)

0.016

Oxygen therapy

No

337/1869 (18)

Reference

 

Reference

 

Yes

120/1086 (11)

0.6 (0.4-0.7)

<0.001

0.7 (0.5- 0.9)

0.007

Receiving TB treatment at time of admission

No

25/158 (16)

Reference

   

Yes

10/49 (20)

1.4 (0.6-3.1)

0.456

  

Started on TB treatment

No

205/2301 (9)

Reference

 

Reference

 

Yes

251/647 (39)

6.5 (5.2-8.0)

<0.001

4.6 (3.5-6.0)

<0.001

Duration of hospitalisation (days)

≤7

279/1913 (14)

Reference

   

>7

174/1029 (17)

1.2 (0.96-1.6)

0.096

  

Season

Summer

57/366 (15)

Reference

   
 

Autumn

78/449 (17)

1.1 (0.8-1.6)

0.492

  
 

Winter

178/1027 (17)

1.1 (0.8-1.6)

0.441

  
 

Spring

144/1117 (13)

0.8 (0.6-1.1)

0.194

  

Died

No

421/2757 (15)

Reference

   
 

Yes

35/195 (18)

1.2 (0.8-1.8)

0.318

  

HIV – human immunodeficiency virus; ICU– Intensive Care Unit, TB-Tuberculosis, CI – confidence interval.

Analysis includes 2029 individuals with severe acute respiratory illness and 930 with severe chronic respiratory illness.

*Underlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus, immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.

**lyt A PCR positive for Streptococcus pneumoniae on blood specimen.

Other variables that were evaluated but not presented in the table because they were not significant on univariate analysis were sex, influenza type, concurrent bacterial infection, antibiotic prescribed on admission, admission to intensive care unit, and smoking and alcohol intake for patients ≥12 years.

HIV results were available for 93% (424/457) of tuberculosis-positive and 92% (2315/2502) of tuberculosis-negative individuals. Of these, 335 (79%) of tuberculosis-positive and 1542 (67%) of tuberculosis-negative individuals were HIV infected. Amongst tuberculosis-positive patients tested for HIV, age-specific HIV prevalence were 36% (15/42), 79% (35/44), 95% (222/234), 65% (58/89), 33% (5/15) in the <5 years, 5–24 years, 25–44 years, 45–64 years and ≥65 years age groups, respectively. Amongst tuberculosis-negative patients tested for HIV, age-specific HIV prevalence were 19% (78/417), 71% (147/206), 89% (966/1081), 65% (325/502) and 24% (26/109) in the <5 years, 5–24 years, 25–44 years, 45–64 years and ≥65 years age groups, respectively.

Factors associated with tuberculosis and influenza infection

Among the 2959 patients with available tuberculosis and influenza results, 2227 (75%) were negative for both pathogens, 423 (14%) were positive for tuberculosis alone, 275 (9%) were positive for influenza alone and 34 (1%) had influenza and tuberculosis co-infection. Tuberculosis treatment was being received at the time of admission for 2% (n = 10) of patients positive for tuberculosis only and <1% (n = 2) of patients positive for influenza only. None of the patients with influenza and tuberculosis co-infection were on tuberculosis treatment at the time of admission.

On multivariable analysis adjusting for age group, patients infected with influenza only compared to patients with tuberculosis only were less likely to be HIV infected (adjusted relative risk ratio (aRRR) 0.6, 95% CI 0.4-0.9), to present with duration of symptoms ≥7 days (aRRR 0.3, 95% CI 0.2-0.4), to be admitted for longer than 7 days (aRRR 0.6, 95% CI 0.4-0.9) while they were more likely to be started on oxygen therapy (aRRR 1.9, 95% CI 1.3-2.8) (Table 3). Patients co-infected with tuberculosis and influenza compared to patients with tuberculosis only were less likely to present with symptoms ≥7 days (aRRR 0.3, 95% CI 0.1-0.7), but were at increased risk of death (aRRR 3.1, 95% CI 1.1-10.1).
Table 3

Factors associated with influenza infection and tuberculosis-influenza co-infection compared with tuberculosis infection only in patients admitted with severe respiratory illness (acute and chronic) and tested for tuberculosis and influenza at four sites in South Africa, June 2010- December 2011

Variables

 

Laboratory confirmed tuberculosis Referencea

Laboratory confirmed influenza

Laboratory confirmed tuberculosis-influenza co-infection

n/N (%)

RRRb

ARRRc(95% CI)

n/N (%)

RRRb

ARRRc(95% CI)

Age group (years)

0-4

47/423 (11)

46/275 (10)

Reference

Reference

8/34 (22)

Reference

Reference

5-24

44/423 (10)

28/275 (11)

0.6 (0.3-1.2)

1.3 (0.6-2.9)

3/34 (9)

0.4 (0.1-1.6)

0.5 (0.1-2.5)

 

25-44

231/423 (55)

121/275 (44)

0.5 (0.3-0.8)

1.5 (0.8-2.8)

18/34 (53)

0.5 (0.2-1.2)

0.5 (0.2-1.7)

 

45-64

86/423 (20)

57/275 (21)

0.7 (0.4-1.1)

1.3 (0.7-2.5)

4/34 (12)

0.3 (0.1-0.9)

0.3 (0.1-2.5)

 

65+

15/423 (3)

23/275 (8)

1.6 (0.7-3.4)

3.9 (1.6-9.8)

1/34 (3)

0.3 (0.04-3.4)

9.53e-07

Sex

Female

247/423 (58)

176/275 (64)

Reference

 

20/34 (59)

Reference

 
 

Male

176/176 (42)

99/275 (36)

0.8 (0.6-1.1)

 

14/34 (41)

1.0 (0.5-1.9)

 

Site

Chris Hani Baragwanath

124/423 (29)

169/275 (61)

Reference

 

17/34 (50)

Reference

 
 

Mapulaneng & Matikwana

21/423 (5)

11/275 (4)

0.4 (0.2-0.8)

 

2/34 (6)

0.7 (0.1-3.2)

 
 

Edendale

48/423 (11)

22/275 (8)

0.3 (0.2-0.6)

 

1/34 (3)

0.2 (0.01-1.2)

 
 

Klerksdorp/Tshepong

230/423 (54)

73/275 (27)

0.2 (0.2-0.3)

 

14/34 (41)

0.4 (0.2-0.9)

 

HIV status

Negative

82/392 (21)

99/257 (39)

Reference

Reference

7/32 (22)

Reference

Reference

Positive

310/392 (79)

158/257 (61

0.4 (0.3-0.6)

0.6 (0.4-0.9)

25/32 (78)

0.9 (0.4-2.3)

1.6 (0.5-4.9)

Underlying medical conditionsd

No

394/423 (93)

240/275 (87)

Reference

 

32/34 (94)

Reference

 

Yes

29/423 (7)

35/275 (13)

1.98 (1.2-3.3)

 

2/34 (6)

0.8 (0.2-3.7)

 

Duration of symptoms prior to admission

<7

166/412 (40)

194/275 (71)

Reference

Reference

24/33 (73)

Reference

Reference

≥7

246/412 (60)

81/275 (29)

0.3 (0.2-0.4)

0.4 (0.2-0.4)

9/33 (27)

0.3 (0.1-0.6)

0.3 (0.1-0.7)

Pneumoccocal co-infection on PCRe

No

371/388 (96)

233/246 (95)

Reference

Reference

29/30 (97)

  

Yes

17/388 (4)

13/246 (5)

1.2 (0.6-2.6)

 

1/30 (3)

0.8 (0.1-5.8)

 

Oxygen therapy

No

313/423 (74)

158/275 (57)

Reference

Reference

24/34 (71)

Reference

Reference

 

Yes

110/423 (26)

117/275 (43)

2.1 (1.5-2.9)

1.9 (1.3-2.8)

10/34 (29)

1.2 (0.5-2.6)

0.97 (0.4-2.3)

Tuberculosis treatment

No

185/422 (44)

243/274 (89)

Reference

 

20/34 (59)

Reference

 

Yes

237/422 (56)

31/274 (11)

0.1 (0.1-0.2)

 

14/34 (41)

0.5 (0.3-1.1)

 

Hospital duration (days)

≤

257/420 (61)

198/274 (72)

Reference

 

22/33 (67)

Reference

Reference

>7

163/420 (39)

76/274 (28)

0.6 (0.4-0.8)

0.6 (0.4-0.9)

11/33 (33)

0.8 (0.4-1.7)

0.7 (0.3-1.5)

Died

No

391/422 (73)

265/274

Reference

Reference

30/34 (88)

Reference

Reference

 

Yes

31/422 (7)

9/274

0.4 (0.2-0.9)

0.5 (0.2-1.1)

4/34 (12)

1.7 (0.6-5.1)

3.2 (1.1-10.0)

aTuberculosis only group used as reference for multinomial model analysis (i.e. comparing influenza only to tuberculosis only and tuberculosis–influenza co-infection to tuberculosis only group).

bUnadjusted relative risk ratio (RRR) at multivariable analysis.

cAdjusted relative risk ratio (ARRR) at multivariable analysis.

dUnderlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus, immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulindeficiency, malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.

elyt A PCR positive for Streptococcus pneumoniae on blood specimen.

Of the 720 patients testing positive for influenza and/or tuberculosis, 384 (53%) presented with symptom duration <7 days. Of these, 166 (43%) were positive for tuberculosis alone, 194 (50%) were positive for influenza alone and 24 (6%) had tuberculosis-influenza co-infection. Of the 336/720 (47%) patients testing positive for influenza and/or tuberculosis with symptom duration ≥7 days, 246 (73%) were positive for tuberculosis alone, 81 (24%) were positive for influenza alone and 9 (3%) had tuberculosis-influenza co-infection. The median duration of symptoms was 2 (range 0–6) and 14 (7–195) days in patients presenting with symptoms <7 days and ≥7 days respectively.

On multivariable analysis, among patients presenting with symptoms <7 days, patients with influenza only compared to patients with tuberculosis only were less likely to be admitted for >7 days (aRRR 0.4, 95% CI 0.3-0.7). No differences were found in patients co-infected with tuberculosis and influenza compared to patients with tuberculosis only and there was no increased risk of death in influenza tuberculosis co-infected individuals (aRRR 0.8, 95% CI 0.1-8.6) (Table 4).
Table 4

Factors associated with influenza infection and tuberculosis-influenza co-infection compared with tuberculosis infection only among patients presenting with symptoms duration <7 days admitted with severe respiratory illness and tested for tuberculosis and influenza at four sites in South Africa, June 2010-2011

Variables

 

Laboratory confirmed tuberculosis Referencea

Laboratory confirmed influenza

Laboratory confirmed tuberculosis-influenza co-infection

n/N (%)

ARRRb

P-value

n/N (%)

ARRRb

P-value

Duration of symptoms

<7

100/165 (61)

148/194 (76)

Reference

 

6/9 (67)

Reference

 

≥7 days

65/165 (39)

46/194 (24)

0.4 (0.3-0.7)

0.001

3/9 (33)

0.5 (0.2-1.5)

0.240

HIV status

Negative

46/148 (31)

74/179 (41)

Reference

 

5/22 (23)

Reference

 
 

Positive

102/148 (69)

105/ 179 (59)

0.8 (0.5-1.2)

0.280

17/22 (77)

1.6 (0.5-4.7)

0.404

Oxygen therapy

No

101/166 (61)

108/194 (56)

Reference

 

17/24 (71)

Reference

 

Yes

65/166 (39)

86/194 (44)

1.4 (0.9-2.3)

0.141

7/24 (29)

0.7 (0.3-2.0)

0.560

Died

No

157/166 (95)

191/194 (98)

0.5(0.2-1.5)

 

24/24 (96)

Reference

 
 

Yes

9/166 (5)

3/194 (2)

0.2 (0.04-1.2)

0.081

1/24 (4)

0.98 (0.1-8.6)

0.986

HIV – human immunodeficiency virus.

aTuberculosis only group used as reference for multinomial model analysis (i.e. comparing influenza only to tuberculosis only and tuberculosis–influenza co-infection to tuberculosis only group).

bAdjusted relative risk ratio (ARRR) at multivariable analysis.

On multivariable analysis among patients presenting with symptoms ≥7 days, patients with influenza only compared to tuberculosis only were less likely to be HIV-infected (aRRR 0.4, 95% CI 0.2-0.7) and more likely to receive oxygen (aRRR 1.7, 95% CI 1.7-5.4). Patients co-infected with tuberculosis and influenza as compared to patients with tuberculosis only were at increased risk of death (aRRR 5.5, 95% CI 1.2-25.3) (Table 5).
Table 5

Factors associated with influenza infection and tuberculosis-influenza co-infection compared with tuberculosis infection only among patients admitted with severe respiratory illness presenting with symptoms duration ≥7 days and tested for tuberculosis and influenza at four sites in South Africa, June 2010- December 2011

Variables

 

Laboratory confirmed tuberculosis Referencea

Laboratory confirmed influenza

Laboratory confirmed tuberculosis-influenza co-infection

n/N (%)

ARRRb

P-value

n/N (%)

ARRRb

P-value

Hospital duration

<7

150/244 (61)

50/80 (62.5)

Reference

 

6/9 (67)

Reference

 

≥7 days

94/244 (39)

30/80 (37.7)

0.99 (0.6-1.7)

0.991

3/9 (33)

0.6 (0.1-2.7)

0.520

HIV status

Negative

34/233 (83)

25/78 (32)

Reference

 

1/9 (11)

Reference

 
 

Positive

199/233 (17)

53/78 (68)

0.4 (0.2-0.7)

0.002

8/9 (89)

2.2 (0.2-20.5)

0.486

Oxygen therapy

No

203/246 (83)

50/81 (62)

Reference

 

6/9 (67)

Reference

 

Yes

43/246 (17)

31/81 (38)

3.0 (1.7-5.5)

<0.001

3/9 (33)

2.1 (0.5-9.3)

0.315

Died

No

224/245 (91)

74/80 (92.5)

Reference

 

6/9 (67)

Reference

 
 

Yes

21/245 (9)

6/80 (7.5)

0.54 (0.2-1.5)

0.875

3/9 (33)

5.48 (1.2-25.4)

0.029

HIV – human immunodeficiency virus.

aTuberculosis only group used as reference for multinomial model analysis (i.e. comparing influenza only to tuberculosis only and tuberculosis–influenza co-infection to tuberculosis only group).

bAdjusted relative risk ratio (ARRR) at multivariable analysis.

Discussion

We describe an increased risk of death associated with influenza co-infection among patients with symptoms ≥7 days hospitalized with laboratory-confirmed tuberculosis in South Africa. Mortality was not increased in patients co-infected with influenza and tuberculosis presenting with a more recent symptom onset. This suggests that influenza infection may contribute to a proportion of the mortality burden amongst patients with tuberculosis, in particular amongst those with a longer duration of symptoms. Because influenza illness is considered to be an acute infection it is possible that it is not considered as a possible diagnosis in patients with longer duration of symptoms. Both influenza and tuberculosis should be considered and tested for among patients hospitalized with pneumonia in settings with high tuberculosis prevalence such as South Africa. Based on the findings of this study our surveillance programme has been amended at two sites to include systematic testing for tuberculosis in patients admitted with severe respiratory illness. In addition, we suggest that where possible tuberculosis testing should be included in SARI programmes in Sub-Saharan Africa where HIV prevalence is high.

A recent study from Thailand did not identify an increased risk of severe outcomes or mortality in patients co-infected with tuberculosis and seasonal influenza when compared to tuberculosis and influenza single infection [18]. The number of patients co-infected with influenza and tuberculosis in this study were, however, small, and patients with a more chronic presentation were not enrolled in the surveillance system. Similar to the findings of our study, ecological and record review studies have reported elevated mortality among tuberculosis-infected individuals during previous influenza pandemics [9,10,19] and 10% of A(H1N1)pdm09 laboratory-confirmed deaths in South Africa in 2009, were co-infected with tuberculosis [11].

In patients presenting with longer duration of symptoms, tuberculosis may have caused lung damage leading to reduced lung capacity and thus impairing the ability to cope with viral infections such as influenza and potentially increasing the severity of illness associated with influenza virus infection. In addition, influenza infection impacts on antibacterial host defenses by either increased production of pro-inflammatory cytokines, causing cell damage [20], or due to inadequate pro-inflammatory chemokine response [21,22], which could increase susceptibility to tuberculosis. Lastly, immunosuppression induced by influenza virus through production of glucocorticoids [23], production of immunosuppressive cytokines [20] or, suppression of T-cell immunity [24] could trigger reactivation of latent tuberculosis and aggravate pulmonary tuberculosis.

Persons with AIDS experience a significant excess mortality due to influenza infection as compared to HIV-uninfected individuals [7,25]. The relative risk of M. tuberculosis infection among HIV-infected compared to -uninfected persons varies between 21–37 depending on the country’s HIV prevalence [2]. In our study, a high proportion of patients with tuberculosis were also HIV-infected; however the association with increased mortality in patients co-infected with tuberculosis and influenza virus remained statistically significant even when controlling for concurrent HIV infection in the model.

Despite the high prevalence of tuberculosis in South Africa, in our study, only 37% (3018/8032) of patients admitted with SRI were tested for tuberculosis. Even amongst patients who were initiated on tuberculosis treatment during the current admission, only 58% (656/1123) were tested before initiation of treatment. A study conducted in South Africa reported tuberculosis as the most common cause (40%) of community acquired pneumonia in both HIV-infected and-uninfected patients [26]. A post mortem study in patients dying in hospital found that among patients not suspected of having tuberculosis at time of death, 42% (40/96) were culture positive for tuberculosis and that pneumonia, was the leading admission diagnosis (25%) in those not suspected of tuberculosis [27]. Only 32% of patients with symptom duration of <7 days were tested for tuberculosis, as compared to 57% in those with a chronic presentation, but amongst those tested, 10% had laboratory confirmed-tuberculosis. National guidelines for tuberculosis management advise screening for tuberculosis in patients presenting with persistent chronic symptoms (cough or fever >14 days) [28], however results from a pooled analysis of sensitivity of symptoms for active pulmonary tuberculosis, showed that in studies from sub-Saharan countries, with high burden of HIV, sensitivity of any cough was higher 62% than that of chronic cough >2 weeks, 49% [29]. Failure to test for tuberculosis could lead to delayed or missed diagnosis of tuberculosis, an increase in nosocomial tuberculosis transmission and missed opportunities to identify drug resistance when testing with the GeneXpert assay. Because of the long duration of tuberculosis treatment and possible associated adverse events, a microbiologic diagnosis of tuberculosis should be sought wherever possible [30]. The majority of tuberculosis-positive patients in our study were aged >5 years. Microbiological confirmation of tuberculosis in children is difficult [14,31-34], because childhood tuberculosis tends to be paucibacillary and smear negative. This difficulty can be further compounded by HIV co-infection.

Less than 1% of patients in our study received influenza antiviral treatment or influenza vaccination despite being recommended in national guidelines [35,36]. The association between influenza and tuberculosis seen in our study may be different in settings where influenza vaccination and antivirals are widely used. In South Africa, while there are recommendations for annual influenza vaccination, tuberculosis is not specifically listed as an underlying co-morbid illness to be targeted for vaccination [37]. Tuberculosis treatment guidelines do not routinely include influenza vaccination as part of management [15]. A randomised controlled study of trivalent inactivated influenza vaccine conducted in HIV-infected adults with CD4+ T cell counts >200 μg/ml in South Africa reported 75% (95% CI 9.2-95.6) efficacy in adults [38]. However, patients with tuberculosis co-infection or low CD4+ T cell counts were not included. Although vaccination remains the most effective method to prevent influenza infection, tuberculosis infection suppresses immune responses and thus vaccine effectiveness may be lower in this patient group. There are no published data on the effectiveness of influenza vaccination in patients with tuberculosis, particularly those co-infected with HIV (79% of individuals in our study).

Our study has limitations that warrant discussion. Firstly, we restricted our analysis to patients with tuberculosis laboratory results at current admission, and our case definition of laboratory-confirmed tuberculosis included smear-positive results. As testing for tuberculosis is not 100% sensitive, especially for extra pulmonary tuberculosis which is common in patients with HIV, we may have misclassified a proportion of tuberculosis-positive individuals as not having tuberculosis; however there is no reason to suspect that sensitivity would differ between influenza-positive and -negative patients. The majority of patients with laboratory-confirmed tuberculosis only had microscopy results and it is possible that some may have been infected with mycobacteria other than tuberculosis in a high HIV prevalence setting such as South Africa. However, current South African guidelines recommend initiation of tuberculosis treatment based on smear microscopy results [11]. Secondly we enrolled acute and chronic cases only at two enhanced sites and we didn’t systematically test all enrolled cases for tuberculosis. The patients tested for tuberculosis differed in several characteristics from those not tested. These differences in enrolment and testing procedures as well as the low proportion of patients tested for tuberculosis may have introduced potential selection bias in the population included in the study. Testing all patients admitted with SRI will improve identification of tuberculosis cases and the ability to detect significant differences between groups. We did not collect data on chest X- ray findings. Availability of data on radiological changes in the lungs could have strengthened the evidence in support of our hypothesis regarding changes in the lungs resulting in severe outcome in patients with underlying tuberculosis co-infected with influenza.

Conclusion

In conclusion, we observed an increased risk of death among tuberculosis-infected patients co-infected with influenza with a symptom history of ≥7 days. The potential public health impact of influenza vaccination among persons with laboratory-confirmed tuberculosis should be explored.

Abbreviations

AIDS: 

Acquired immune deficiency syndrome

ALRI: 

Acute lower respiratory tract infection

aOR: 

adjusted odds ratio

aRRR: 

Adjusted relative risk ratio

CDC: 

Centers for Disease Control

CHBAH: 

Chris Hani Baragwanath Academic Hospital

ELISA: 

Enzyme-linked immunosorbent assay

HIV: 

Human immunodeficiency virus

KTHC: 

Klerksdorp Tshepong Hospital Complex

ICU: 

Intensive care unit

M. tuberculosis : 

Mycobacterium tuberculosis

NICD-NHLS: 

National Institute for Communicable Diseases of the National Health Laboratory Services

PCR: 

Polymerase chain reaction

RR: 

Relative risk

RRR: 

Relative risk ratio

SARI: 

Severe acute respiratory illness

SCRI: 

Severe chronic respiratory illness

S. pneumoniae : 

Streptococcus. pneumoniae

SRI: 

Severe respiratory illness

WHO: 

World Health Organization

Declarations

Acknowledgements

We would like to thank patients from the surveillance sites for their participation in the study, surveillance officers and clinicians from the sites and the data team that worked on the project.

Authors’ Affiliations

(1)
Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Private Bag X4, Sandringham, 2131 Johannesburg, Gauteng, South Africa
(2)
School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
(3)
US Centres for Disease Control and Prevention, Atlanta, GA, USA
(4)
US Centres for Disease Control and Prevention, Pretoria, South Africa
(5)
Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine-Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa
(6)
Pietermaritzburg Metropolitan Hospital Complex, KwaZulu- Natal, South Africa
(7)
MRC/Wits Rural Public Health and Health Transition Research Unit (Agincourt), Bushbuckridge, South Africa
(8)
Tshepong Hospital, North West Province, South Africa
(9)
Faculty of Medicine, University of Witwatersrand, Johannesburg, South Africa
(10)
Zoonosis Research Unit, Department of Medical Virology, University of Pretoria, Pretoria, South Africa

References

  1. World Health Organization. Global Tuberculosis Report 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf. Accessed 18 December 2014.
  2. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. http://whqlibdoc.who.int/publications/2009/9789241563802_eng_doc.pdf. Accessed 18 December 2014.
  3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50 Suppl 3:S201–7.View ArticlePubMedGoogle Scholar
  4. World Health Organization. Seasonal influenza. In. WHO website 2014. http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed 18 December 2014.
  5. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013. 1917–1930.Google Scholar
  6. MMWR Morb Mortal Wkly Rep 2010. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. August 6, 2010 / 59(RR008) pp. 1–62. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm. Accessed 20/01/2015.
  7. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, et al. Influenza-related mortality among adults aged 25–54 years with AIDS in South Africa and the United States of America. Clin Infect Dis. 2012;55:996–1003.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Noymer A. Testing the influenza-tuberculosis selective mortality hypothesis with Union Army data. Soc Sci Med. 2009;68:1599–608.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Noymer A. The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: an age, period, cohort analysis. Vaccine. 2011;29 Suppl 2:B38–41.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Oei W, Nishiura H. The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918–19. Comput Math Methods Med. 2012;2012:124861.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Archer B, Cohen C, Naidoo D, Thomas J, Makunga C, Blumberg L, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009;14(42).Google Scholar
  12. Noh JY, Lee J, Choi WS, Song JY, Seo YB, Kim IS, et al. Concurrent tuberculosis and influenza, South Korea. Emerg Infect Dis. 2013;19:165–7.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius MA, et al. Severe influenza-associated lower respiratory tract infection in a high HIV-prevalence setting-South Africa, 2009–2011. Clinical Infect Dis. 2013;19(11):1766–74.Google Scholar
  14. World Health Organization. WHO global technical consultation: global standards and tools for influenza surveillance. 2011. http://whqlibdoc.who.int/hq/2011/WHO_HSE_GIP_2011.1_eng.pdf. Accessed 18 December 2014.
  15. National Department of Health. National Tuberculosis Management Guidelines 2009. http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx; 2009. pp. 1–116. Accessed 18 December 2014.
  16. Pretorius MA, Madhi SA, Cohen C, Naidoo D, Groome M, Moyes J, et al. Respiratory viral coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness–South Africa, 2009–2010. J Infect Dis. 2012;206 Suppl 1:S159–65.View ArticlePubMedGoogle Scholar
  17. Carvalho MG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol. 2007;45:2460–6.View ArticlePubMed CentralGoogle Scholar
  18. Roth S, Whitehead S, Thamthitiwat S, Chittaganpitch M, Maloney SA, Baggett HC, et al. Concurrent influenza virus infection and tuberculosis in patients hospitalized with respiratory illness in Thailand. Influenza Other Respi Viruses. 2012;7:244–8.View ArticleGoogle Scholar
  19. Noymer A, Garenne M. The 1918 influenza epidemic's effects on sex differentials in mortality in the United States. Popul Dev Rev. 2000;26:565–81.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Speshock JL, Doyon-Reale N, Rabah R, Neely MN, Roberts PC. Filamentous influenza A virus infection predisposes mice to fatal septicemia following superinfection with Streptococcus pneumoniae serotype 3. Infect Immun. 2007;75:3102–11.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009;119:1910–20.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Small CL, Shaler CR, McCormick S, Jeyanathan M, Damjanovic D, Brown EG, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol. 2010;184:2048–56.View ArticlePubMedGoogle Scholar
  23. Jamieson AM, Yu S, Annicelli CH, Medzhitov R. Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe. 2010;7:103–14.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Jiang TJ, Zhang JY, Li WG, Xie YX, Zhang XW, Wang Y, et al. Preferential loss of Th17 cells is associated with CD4 T cell activation in patients with 2009 pandemic H1N1 swine-origin influenza A infection. Clin Immunol. 2010;137:303–10.View ArticlePubMedGoogle Scholar
  25. Lin JC, Ichol K. Excess Mortality Due to Pneumonia or Influenza During the Influenza Seasons Among Persons with Acquired Immunodeficiency Syndrome. Arch Intern Med. 2001;161(2001):441–6c.View ArticlePubMedGoogle Scholar
  26. Nyamande K, Lalloo UG, John M. TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence. Int J Tuberc Lung Dis. 2007;11:1308–13.PubMedGoogle Scholar
  27. Cohen T, Murray M, Wallengren K, Alvarenz G, Samuel E, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLos Med. 2010;7(6):e1000296.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Department of Health. National Tuberculosis Management Guidelines. 2014. pp. 1–116. http://www.sahivsoc.org/upload/documents/NTCP_Adult_TB%20Guidelines%2027.5.2014.pdf. Accessed 18 December 2014.
  29. van’t Hoog AH LM, Mitchell E, Cobelens FG, Sinclair D, Leeflang MMG, Lonnroth K. A systematic review of the sensitivity and specificity of symptom- and chest-radiography . World Health Organization; 2013. Accessed at http://www.who.int/tb/Review2Accuracyofscreeningtests.pdf.
  30. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care. World Health Organization website; 2006. http://www.who.int/tb/publications/2006/istc_report_shortversion.pdf. Accessed 18 December 2014.
  31. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005;365:130–4.View ArticlePubMedGoogle Scholar
  32. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis (Edinb). 2003;83:208–12.View ArticleGoogle Scholar
  33. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis. 2003;3:624–32.View ArticlePubMedGoogle Scholar
  34. Zar HJ, Tannenbaum E, Hanslo D, Hussey G. Sputum induction as a diagnostic tool for community-acquired pneumonia in infants and young children from a high HIV prevalence area. Pediatr Pulmonol. 2003;36:58–62.View ArticlePubMedGoogle Scholar
  35. National Institute for Communicable Diseases, South African National Department of Health. Healthcare Workers Handbook on Influenza. In; 2012. http://www.nicd.ac.za/assets/files/Healthcare%20Workers%20Handbook%20on%20Influenza%20in%20SA%20_12%20May%202014%281%29.pdf. Accessed 18 December 2014.
  36. Schoub BD. Recommendations pertaining to the use of viral vaccines: influenza 2009. S Afr Med J. 2009;99:87.PubMedGoogle Scholar
  37. Schoub BD. Recommendations pertaining to the use of viral vaccines: influenza 2012. S Afr Med J. 2012;102:73.View ArticlePubMedGoogle Scholar
  38. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52:128–37.View ArticlePubMedGoogle Scholar

Copyright

© Walaza et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us